Navigation Links
INFORMS study: OR models of hepatitis B prove decisive in treating millions in US, China
Date:7/26/2011

With hepatitis B infecting as many as 10% of people of Asian descent, operations researchers collaborated with a liver transplant surgeon to develop mathematical models that verified the cost effectiveness of hepatitis B interventions. These interventions now successfully screen, treat, and vaccinate millions of Asian and Pacific Islander adults in the U.S. and millions of children in China, according to a paper in a journal of the Institute for Operations Research and the Management Sciences (INFORMS).

Untreated, hepatitis B can become a chronic, lifelong disease that leads to liver cancer and cirrhosis.

Chinese health officials were considering a program of catch-up vaccinations for children who had not been vaccinated at birth, but were reluctant to commit funds to a widespread hepatitis B catch-up vaccination program until analysis confirmed its cost-effectiveness.

The authors' analysis of the program's cost effectiveness influenced the Chinese government's April 2009 decision to expand free catch-up vaccination to all children in China under the age of 15.

They estimate that this decision could result in almost 170 million children being vaccinated and could prevent almost 8 million acute infections, 400,000 chronic infections, and almost 70,000 deaths. The vaccinations would cost the equivalent of $540 million and save the equivalent of $1.4 billion over the lifetime of these children, for a net present savings of approximately $900 million.

Additionally, they would spare hundreds of thousands of Chinese children from facing a lifetime of discrimination those infected with hepatitis B in China, according to reports, are often denied the right to attend school or enter the workplace.

In the U.S., they evaluated four clinical strategies. Of the four, they concluded that it is most cost-effective to adopt a strategy of screening adult Asian and Pacific Islanders for chronic hepatitis B infection so that those identified can receive treatment. They also found it cost-effective to vaccinate those in close contact with the infected so they can be protected from contagion.

Using a common public health metric, they estimate that it costs $36,000$40,000 per quality-adjusted life year (QALY) gained to screen and provide treatment for adult Asian and Pacific Islanders. In the U.S., an intervention that costs less than $50,000 per QALY gained is generally considered to be cost effective.

The total cost of treating chronically infected people in the U.S. is more than 100 times greater than the cost of the initial screening program. The study provided the convincing evidence that led to the 2010 Institute of Medicine report on Hepatitis and Liver Cancer, as well as the 2011 Health and Human Services' Action Plan to combat the silent epidemic of viral hepatitis and recommend routine screening of foreign born including Asians in the U.S. for chronic hepatitis B infection.

"Doing Good with Good O.R. [Operations Research]: Supporting Cost-Effective Hepatitis B Interventions" is by David W. Hutton and Margaret L. Brandeau of the Department of Management Science and Engineering at Stanford University and Samuel K. So of the Stanford University School of Medicine's Asian Liver Center and Department of Surgery. It appears in a special issue of the INFORMS journal Interfaces that is dedicated to the new, growing field of humanitarian applications in operations research, which applies analytical and mathematical models to benefit the public sector.

"Doing Good with Good O.R." is a program initiated by INFORMS that encourages operations researchers to make major improvements in the public sector using their specialized skills.

With budgets for healthcare chronically tight, the authors evaluated several potential hepatitis B screening, vaccination, and treatment interventions in order to identify the most cost-effective as measured in health benefits per dollar spent.

They used new combinations of decision analysis and Markov models to analyze several interventions.

"Increasingly in medicine, policymakers are looking for evidence of effectiveness and cost-effectiveness to support their decision making," writes Alena Groopman, Global Health Coordinator at the Asian Liver Center. "Typically, conducting clinical trials of HBV [hepatitis B] policies would take decades to gather this evidence. The work that David Hutton, Dr. Margaret Brandeau, and Dr. Sam So have done modeling this disease and these interventions has been incredibly important to accelerating policy changes to improve health related to HBV."

The team was able to achieve their results in approximately a year.


'/>"/>

Contact: Barry List
barry.list@informs.org
443-757-3560
Institute for Operations Research and the Management Sciences
Source:Eurekalert

Related medicine news :

1. INFORMS: CARE positions disaster relief with promising discipline of humanitarian logistics
2. INFORMS journal announces special issue on using logistics, analytics in humanitarian relief
3. Physician-rating websites are biased, says paper at INFORMS Healthcare conference
4. INFORMS health care conference highlights increased role of math modeling in health systems
5. Study: Doctors differ in how best to care for Americas 12 million cancer survivors
6. Drexel study: Misuse of pain medication is pathway to high-risk behaviors
7. Study: Subsidizing wages at long-term care facilities would cut turnover
8. Study: Inherited Alzheimers Detectable 20 Years Before Symptom Onset
9. Study: Potassium Boosts Heart Health, Salt Harms It
10. Study: Hypoallergenic dogs not less allergic than other dogs
11. New study: Women less likely than men to fake soccer injuries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
(Date:10/12/2017)... ... 2017 , ... Vohra Chief Medical Officer Dr. Shark Bird, ... nursing facility medical directors and other clinicians at various events in October. His ... many of these conferences we get to educate other physicians, facility nurses, corporate ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: